METALERT-STOP | Imaging, characterizing and targeting metastatic niches in melanoma

Summary
Melanomas are the only tumors where lesions barely over one millimeter in depth can be at risk for metastasis. An increasing number of (epi)genetic alterations and mechanisms of immune evasion have been identified in this disease. Nevertheless, no molecular biomarker has been approved as a bona fide prognostic indicator. Progress in this field has been hampered by the paucity of models to visualize premetastatic niches in vivo, and monitor relapse after surgery. We have overcome these limitations by generating reporter mouse strains to “illuminate” premetastatic niches. Specifically, our “MetAlert” mice were designed for whole-body imaging of the aberrant expansion of the lymphatic vasculature, an early event that precedes metastasis. MetAlert, together with functional studies in human cells and histopathological validation in clinical biopsies, revealed the growth factor MIDKINE as a new melanoma-secreted prometastatic driver. We have now discovered roles of MDK as an immune suppressor, and identified a MDK-associated transcriptional profile that separates patients with a distinct expression of alarmins and bacterial response factors. Proteomic analyses revealed a set of additional factors secreted by aggressive melanoma cells, but their specific contribution to premetastatic niches is unclear.

Here we will exploit our MetAlert and novel imaging reporters we have generated for a comprehensive spatio-temporal and functional analysis of premetastatic niches in vivo (including and beyond MDK). We will define how melanomas act “at a distance” before metastasis (Aim 1), and evade the immune system at different anatomical sites (Aim 2). Aim 3 will dissect the impact of the microenvironment, particularly via alarmins. Aim 4 will pursue the therapeutic targeting of metastatic niches (pre and post-surgery) with immunomodulators we discovered (and have led to clinical trials), and by targeting vulnerabilities that we found distinguish melanoma from other diseases.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/884699
Start date: 01-12-2020
End date: 30-11-2025
Total budget - Public funding: 2 497 945,00 Euro - 2 497 945,00 Euro
Cordis data

Original description

Melanomas are the only tumors where lesions barely over one millimeter in depth can be at risk for metastasis. An increasing number of (epi)genetic alterations and mechanisms of immune evasion have been identified in this disease. Nevertheless, no molecular biomarker has been approved as a bona fide prognostic indicator. Progress in this field has been hampered by the paucity of models to visualize premetastatic niches in vivo, and monitor relapse after surgery. We have overcome these limitations by generating reporter mouse strains to “illuminate” premetastatic niches. Specifically, our “MetAlert” mice were designed for whole-body imaging of the aberrant expansion of the lymphatic vasculature, an early event that precedes metastasis. MetAlert, together with functional studies in human cells and histopathological validation in clinical biopsies, revealed the growth factor MIDKINE as a new melanoma-secreted prometastatic driver. We have now discovered roles of MDK as an immune suppressor, and identified a MDK-associated transcriptional profile that separates patients with a distinct expression of alarmins and bacterial response factors. Proteomic analyses revealed a set of additional factors secreted by aggressive melanoma cells, but their specific contribution to premetastatic niches is unclear.

Here we will exploit our MetAlert and novel imaging reporters we have generated for a comprehensive spatio-temporal and functional analysis of premetastatic niches in vivo (including and beyond MDK). We will define how melanomas act “at a distance” before metastasis (Aim 1), and evade the immune system at different anatomical sites (Aim 2). Aim 3 will dissect the impact of the microenvironment, particularly via alarmins. Aim 4 will pursue the therapeutic targeting of metastatic niches (pre and post-surgery) with immunomodulators we discovered (and have led to clinical trials), and by targeting vulnerabilities that we found distinguish melanoma from other diseases.

Status

SIGNED

Call topic

ERC-2019-ADG

Update Date

27-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.1. EXCELLENT SCIENCE - European Research Council (ERC)
ERC-2018
ERC-2019-ADG